CUTERA INC appointed Talyor C. Harris as new CEO

Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On July 27, 2023, Cutera, Inc. (the "Company") announced that Talyor C. Harris had been appointed as the Company's President and Chief Executive Officer, effective as of his first day of employment, which is expected to be August 7, 2023. Mr. Harris has served as a member of the Board of Directors of the Company since May 2023. Mr. Harris served as the Chief Financial Officer for MyoKardia, Inc. from April 2018 until that company's acquisition by Bristol Myers Squibb in November 2020. Prior to that, Mr. Harris served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., until that company's acquisition by Allergan plc. He also served as Vice President and Chief Financial Officer at Thoratec Corporation, which was eventually acquired by St. Jude Medical, Inc and worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm's Healthcare Investment Banking and Equity Research departments. Mr. Harris currently serves on the board of PROCEPT BioRobotics (NASDAQ: PRCT), Omada Health and Endologix. He previously served on the board of HealthCor Catalio Acquisition Corp. Mr. Harris holds a B.A. from the University of North Carolina at Chapel Hill. 

In connection with his appointment as President and Chief Executive Officer, the Company entered into an offer letter with Mr. Harris on July 25, 2023, which provides for, among other things, (i) a base salary of $675,000, (ii) a one-time signing bonus of $300,000 to be paid on March 1, 2024, (iii) annual bonus eligibility beginning with 2024 with a target bonus amount of 100% of salary, (iv) the issuance of a restricted stock award valued at $4,000,000 using the Company's 30 day VWAP immediately preceding the date of grant, and (v) the issuance of an option award valued at $4,000,000 using the Company's standard option valuation practices for accounting purposes, at a strike price equal to the closing price of the Company's common stock on the date of grant. The foregoing summary of the offer letter and equity awards do not purport to be complete and are qualified in their entirety by reference to the full text of the offer letter that is attached hereto as Exhibit 10.1 and incorporated herein by reference. 

Mr. Harris will be eligible to participate in the Company's Executive Change in Control and Severance Policy at a Tier 1 level of severance benefits. Mr. Harris will remain subject to the Company's standard form of indemnification agreement, which was filed as Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on February 21, 2019. 

There are no arrangements or understandings between Mr. Harris and any other persons pursuant to which he was appointed as an officer of the Company. Mr. Harris has no family relationships with any of the Company's directors or executive officers, and, other than as described above, Mr. Harris does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

In connection with Mr. Harris' appointment, Sheila A. Hopkins agreed to resign as interim Chief Executive Officer, effective as of Mr. Harris' first day of employment. Ms. Hopkins will remain a member of the Company's Board of Directors.